ATOS: Atossa Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
32 institutions reported holding $2.60M of Atossa Therapeutics, Inc. on Form 13F (33 the quarter before). 6 opened a new position and 7 sold out. Shares held by institutions: +9%.
| Largest holders | Shares | Value |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 361,747 | $698K |
| AMERIPRISE FINANCIAL INC | 258,234 | $498K |
| BlackRock, Inc. | 164,358 | $317K |
| RENAISSANCE TECHNOLOGIES LLC | 132,043 | $255K |
| GEODE CAPITAL MANAGEMENT, LLC | 92,382 | $178K |
| UBS Group AG | 82,620 | $159K |
| JANE STREET GROUP, LLC | 56,602 | $109K |
| VANGUARD FIDUCIARY TRUST CO | 52,583 | $101K |
| MILLENNIUM MANAGEMENT LLC | 46,508 | $90K |
| STATE STREET CORP | 39,761 | $77K |
Clinical trial readouts
1 Phase 2 or 3 trials by Atossa Therapeutics, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-11 (est.) | (Z)-endoxifen | Breast Neoplasms | Phase 2 | 87 | Enrollment complete | NCT05607004 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.